Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 6Phase 1/2 5Phase 3 3Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

Fluorodeoxyglucose F18 2fluciclovine F-18 1atezolizumab 1X-Rays 1Radium-223 1RXDX-106 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Cell Count 1Aminophylline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Transitional Cell × atezolizumab × Clear all
NCT03208712 2018-10-24

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Terminated
1 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡